355387-54-1Relevant academic research and scientific papers
A regioselective synthesis of 2,4-dialkyl resorcinols
Ceglia, Scott S.,Kress, Michael H.,Nelson, Todd D.,McNamara, James M.
, p. 1731 - 1734 (2005)
A general regioselective synthesis of 2,4-dialkyl resorcinols from ethoxymethylenemalonate ethyl ester and dialkyl ketones is reported.
Design and discovery of 2-oxochromene derivatives as liver X receptor β-selective agonists
Matsuda, Takayuki,Okuda, Ayumu,Watanabe, Yuichiro,Miura, Tohru,Ozawa, Hidefumi,Tosaka, Ayako,Yamazaki, Koichi,Yamaguchi, Yuki,Kurobuchi, Sayaka,Koura, Minoru,Shibuya, Kimiyuki
, p. 1274 - 1278 (2015/03/14)
In an attempt to molecularly design liver X receptor (LXR) β-selective agonists, we discovered that the combination of the 2-oxochromene moiety (head) and the imidazoline-2,4-dione moiety (tail) plays an important role in the expression potency and select
Discovery of a novel series of peroxisome proliferator-activated receptor α/γ dual agonists for the treatment of type 2 diabetes and dyslipidemia
Liu, Kun,Xu, Libo,Berger, Joel P.,MacNaul, Karen L.,Zhou, Gauchao,Doebber, Thomas W.,Forrest, Michael J.,Moller, David E.,Jones, A. Brian
, p. 2262 - 2265 (2007/10/03)
A series of 2-aryloxy-2-methyl-propionic acid compounds and related analogues were designed, synthesized, and evaluated for their PPAR agonist activities. 2-[(5,7-Dipropyl-3-trifluoromethyl)-benzisoxazol-6-yloxy]-2- methylpropionic acid (4) was identified
Aryloxyacetic acids for diabetes and lipid disorders
-
, (2008/06/13)
A class of aryloxyacetic acids comprises compounds that are potent agonists of PPAR alpha and/or gamma, and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyper
O-Arylmandelic acids as highly selective human PPAR α/γ agonists
Adams, Alan D.,Hu, Zao,Von Langen, Derek,Dadiz, Adonis,Elbrecht, Alex,MacNaul, Karen L.,Berger, Joel P.,Zhou, Gaochao,Doebber, Thomas W.,Meurer, Roger,Forrest, Michael J.,Moller, David E.,Jones, A. Brian
, p. 3185 - 3190 (2007/10/03)
A new class of O-arylmandelic acid PPAR agonists show excellent anti-hyperglycemic efficacy in a db/db mouse model of DM2. These PPARα-weighted agonists do not show the typical PPARγ associated side effects of BAT proliferation and cardiac hypertrophy in
Aryloxyacetic acids for diabetes and lipid disorders
-
, (2008/06/13)
A class of aryloxyacetic acids comprises compounds that are potent agonists of PPAR alpha and/or gamma, and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyper
